Tags

Type your tag names separated by a space and hit enter

Antiemetic activity of ondansetron in acute gastroenteritis.
Aliment Pharmacol Ther. 1997 Feb; 11(1):185-91.AP

Abstract

BACKGROUND

The mechanism of nausea and vomiting associated with gastroenteritis is unknown. The role of 5-HT3 receptors in emesis associated with gastroenteritis was investigated in paediatric patients.

METHODS

A randomized, double-blind, placebo-controlled, parallel-group study was conducted in three groups of 12 patients each, receiving either a single i.v. dose of ondansetron (0.3 mg/kg), metoclopramide (0.3 mg/kg) or placebo (sterile saline). Food was restricted and oral rehydration was administered for 4 h.

RESULTS

During 0-24 h, the number of emetic episodes experienced was significantly greater (P = 0.048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (P = 0.039) with ondansetron (58%) than placebo (17%). A numerical difference, in favour of ondansetron, was observed between ondansetron and metoclopramide groups for both of the above parameters. Fewer treatment failures were observed with ondansetron (17%) than placebo (33%) and metoclopramide (42 %). More diarrheal episodes were observed in the groups receiving anti-emetic treatment. All three treatments were well tolerated.

CONCLUSIONS

Ondansetron, a 5HT3 receptor antagonist, was significantly superior to placebo in preventing emesis associated with acute gastroenteritis, in paediatric patients. Therefore, serotonin, acting through 5HT3 receptors, may play a role in this form of emesis.

Authors+Show Affiliations

Department of Pharmacology, School of Pharmacy, Central University of Venezuela, Caracas.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9042992

Citation

Cubeddu, L X., et al. "Antiemetic Activity of Ondansetron in Acute Gastroenteritis." Alimentary Pharmacology & Therapeutics, vol. 11, no. 1, 1997, pp. 185-91.
Cubeddu LX, Trujillo LM, Talmaciu I, et al. Antiemetic activity of ondansetron in acute gastroenteritis. Aliment Pharmacol Ther. 1997;11(1):185-91.
Cubeddu, L. X., Trujillo, L. M., Talmaciu, I., Gonzalez, V., Guariguata, J., Seijas, J., Miller, I. A., & Paska, W. (1997). Antiemetic activity of ondansetron in acute gastroenteritis. Alimentary Pharmacology & Therapeutics, 11(1), 185-91.
Cubeddu LX, et al. Antiemetic Activity of Ondansetron in Acute Gastroenteritis. Aliment Pharmacol Ther. 1997;11(1):185-91. PubMed PMID: 9042992.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antiemetic activity of ondansetron in acute gastroenteritis. AU - Cubeddu,L X, AU - Trujillo,L M, AU - Talmaciu,I, AU - Gonzalez,V, AU - Guariguata,J, AU - Seijas,J, AU - Miller,I A, AU - Paska,W, PY - 1997/2/1/pubmed PY - 1997/2/1/medline PY - 1997/2/1/entrez SP - 185 EP - 91 JF - Alimentary pharmacology & therapeutics JO - Aliment Pharmacol Ther VL - 11 IS - 1 N2 - BACKGROUND: The mechanism of nausea and vomiting associated with gastroenteritis is unknown. The role of 5-HT3 receptors in emesis associated with gastroenteritis was investigated in paediatric patients. METHODS: A randomized, double-blind, placebo-controlled, parallel-group study was conducted in three groups of 12 patients each, receiving either a single i.v. dose of ondansetron (0.3 mg/kg), metoclopramide (0.3 mg/kg) or placebo (sterile saline). Food was restricted and oral rehydration was administered for 4 h. RESULTS: During 0-24 h, the number of emetic episodes experienced was significantly greater (P = 0.048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (P = 0.039) with ondansetron (58%) than placebo (17%). A numerical difference, in favour of ondansetron, was observed between ondansetron and metoclopramide groups for both of the above parameters. Fewer treatment failures were observed with ondansetron (17%) than placebo (33%) and metoclopramide (42 %). More diarrheal episodes were observed in the groups receiving anti-emetic treatment. All three treatments were well tolerated. CONCLUSIONS: Ondansetron, a 5HT3 receptor antagonist, was significantly superior to placebo in preventing emesis associated with acute gastroenteritis, in paediatric patients. Therefore, serotonin, acting through 5HT3 receptors, may play a role in this form of emesis. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/9042992/Antiemetic_activity_of_ondansetron_in_acute_gastroenteritis_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0269-2813&date=1997&volume=11&issue=1&spage=185 DB - PRIME DP - Unbound Medicine ER -